Return-path: <>
Envelope-to: lbaez@edenetsa.com
Delivery-date: Mon, 03 Nov 2014 17:48:33 -0400
Received: from [68.40.151.126] (port=1622 helo=68.40.151.126)
	by host8.dnns.net with smtp (Exim 4.82)
	id 1XlPUH-0000HP-En
	for lbaez@edenetsa.com; Mon, 03 Nov 2014 17:48:33 -0400
Received: from unknown (HELO localhost) (zeb93@ubp.ch@126.139.100.60)
	by 68.40.151.126 with ESMTPA; Mon, 3 Nov 2014 14:43:56 -0500
X-Originating-IP: 126.139.100.60
From: zeb93@ubp.ch
To: lbaez@edenetsa.com
Subject: THIS STOCK IS UP TODAY ON LARGE VOLUME

"Oncolytics Biotech" Biotechnology Firm is focused on the development of 
oncolytic viruses for their further use in the treatment of various forms 
of tumors. The leading company's drug - "REOLYSIN" - is currently in the 
final stage of clinical trials against cancer of head and neck. The 
medicine's action is based on the reovirus (Respiratory Enteric Orphan 
virus) ability to identify and "infect" the cells with the mutated RAS 
gene. After mutation the gene transforms a normal cell into a cancer one. 
"REOLYSIN", made by the Canadian firm "Oncolytics Biotech Inc", not only 
finds the cancer cells with the mutated gene, but also kills them. Provided 
that 2/3 of tumors have cells with the mutated RAS gene, it is hoped that 
complex and even propagating tumors might be treated without radiation and 
chemotherapy.

According to recent data, the application of the reovirus medicine in 
conjunction with chemotherapeutic treatment enlarges the proportion of 
favorable result for the treatment of the head and neck tumors up to 74%.

"Oncolytics Biotech Inc (ONCY)" Company's shares have been presented on 
NASDAQ since 2001, Market Cap 72.36M, rated by Zacks "Strong Buy". As of 
the end of trading on 03/11/2014, the share price was $0.88, which is a 
good entry point for investing in new emerging technologies.

Let us recall that "Oncolytics Biotech Inc" Company was established in 
Calgary in 1998 in response to discoveries made on the oncolytic potential 
of reovirus at the University of Calgary in the 1990s. In 1999-2000 the 
company transitioned from private to public ownership. 

The firm was granted its first Canadian patent in August 2000, and at 
present owns more than 200 patents across the globe, including 38 U.S. and 
11 Canadian patents.